Company News-Bio-Thera Solutions, Ltd.

The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

10-152022

Bio-Thera Solutions Announces Details of Poster Presentation of a Highly Thermal Stable Recombinant Bivalent Nanoparticle Vaccine Containing Spikes of SARS-CoV-2 Omicron and Delta at Vaccine Summit 20

Guangzhou,China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), acommercial-stage biopharmaceutical company, ...
10-152022

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Advanced Solid Tumors

FRα is a folicacid-binding protein located on cell membranes that is overexpressed in avariety of solid tumors such as o...
09-272022

Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company,...

上一页 ···16 17 18 19 20 ··· 下一页